Skip to main content

Table 8 Robustness Results for Lamivudine

From: A new validated stability-indicating RP-HPLC method for simultaneous quantification of dolutegravir and lamivudine in bulk and pharmaceutical dosage form

S. No.

Parameter

As such method

Used

%RSD for peak area (n = 6)

Average retention time

Plate count

Tailing factor

1

Flow rate (± 0.1 mL/min)

1.0 mL/min

0.9 mL/min

0.2

2.374

9457

1.35

1.0 mL/min

0.7

2.169

7651

1.32

1.1 mL/min

1.0

2.152

9145

1.30

2

Column temperature (± 5 °C)

30 °C

25 °C

0.3

2.134

8640

1.25

30 °C

0.7

2.169

7657

1.31

35 °C

1.5

2.150

9128

1.33

3

Mobile phase composition

Buffer:ACN:Methanol, 55:20:30% v/v

55:25:25

0.5

2.136

8648

1.30

55:20:30

0.7

2.169

7653

1.31

55:15:35

0.9

2.164

8475

1.33